Abstract Number: 1558 • 2014 ACR/ARHP Annual Meeting
Evaluation of Extreme Enthesitis and/or Patient-Related Outcome Score As Potential Surrogates for Fibromyalgia and As Potential Confounding Factors of Anti-TNF Response
Background/Purpose: Differentiating between pain related to spondyloarthritis (in particular polyenthesitis) and pain related to fibromyalgia can be challenging, both in daily practice and in clinical…Abstract Number: 1557 • 2014 ACR/ARHP Annual Meeting
Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
Background/Purpose: Interleukin-17 (IL-17) plays a role in the pathogenesis of psoriatic disease of both skin and joint. We sought to assess long-term efficacy and safety…Abstract Number: 1556 • 2014 ACR/ARHP Annual Meeting
Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-up from the Psoriatic Arthritis Clinical Development Program
Background/Purpose: To report the safety of ustekinumab(UST) from the psoriatic arthritis (PsA)development program. Methods: Safety data through up to 2yrs of follow-up were pooled from…Abstract Number: 1533 • 2014 ACR/ARHP Annual Meeting
Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis
Background/Purpose: The treatment of active rheumatoid arthritis (RA) patients are usually started with synthetic disease modifying antirheumatic drugs (DMARDs), but when adequate response are not…Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…Abstract Number: 1531 • 2014 ACR/ARHP Annual Meeting
CUT-Off LEVEL of Adalimumab and Prevalence of Antibodies ANTI-Adalimumab in Patients with Ankylosing Spondylitis: Results from a LOCAL Registry
Background/Purpose To evaluate the Cut-off level of adalimumab (ADL) and the prevalence of antibodies anti-adalimumab (anti-ADL-ab), in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS).…Abstract Number: 1530 • 2014 ACR/ARHP Annual Meeting
Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis
Background/Purpose Rheumatoid arthritis (RA) is a chronic autoimmune disease which results from a breakdown of immune tolerance. Despite their efficacy current RA therapeutics, including biologic…Abstract Number: 1529 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Pharmacokinetics and Safety of the Interactions Between the Anti-Interleukin-6 Monoclonal Antibody Sirukumab and Cytochrome P450 Activities in Patients with Rheumatoid Arthritis
Background/Purpose: Interleukin 6 (IL-6) reduces the expression of cytochrome P450 (CYP) enzymes. The goal of the study was to evaluate: 1) the effect of sirukumab…Abstract Number: 1528 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies
Background/Purpose: Novel, targeted small-molecular medications are needed in the treatment of rheumatoid arthritis (RA). MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK)…Abstract Number: 1526 • 2014 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy after Multiple Courses of Rituximab in Rheumatoid Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: 3-Year DataÂ
Background/Purpose Efficacy and safety of multiple courses of biologics used over extended periods of time in rheumatoid arthritis (RA) is still a medical debate. The…Abstract Number: 1527 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison
Background/Purpose: To date, no head-to-head trials have been conducted comparing the efficacy of biologic treatments for early active rheumatoid arthritis (ERA). Here, we evaluated the…Abstract Number: 1525 • 2014 ACR/ARHP Annual Meeting
Cumulative Clinical  Response in  Rheumatoid Arthritis Patients with  Rituximab Repeated Courses after Failure to Tumor Necrosis Factor Inhibitors in Routine Clinical Practice Â
Background/Purpose The concept of achieving tight control of rheumatoid arthritis (RA) and treating to target has been well established. It focuses on early diagnosis, aggressive…Abstract Number: 1524 • 2014 ACR/ARHP Annual Meeting
Rituximab Done! What’s Next in RA?
Background/Purpose The optimal strategy to use biologics after rituximab (RTX) in RA is unknown. We therefore aimed to evaluate the effectiveness of different biologics after…Abstract Number: 1523 • 2014 ACR/ARHP Annual Meeting
Follow-up Data on the Rheumatoid Arthritis Comparison of Active Therapies Trial: Observational Cohort
Background/Purpose In this 48-week, double-blinded, non-inferiority trial, 353 methotrexate suboptimal-responders were randomized to two treatment strategies, either the addition of sulfasalazine and hydroxychloroquine (triple therapy…Abstract Number: 1542 • 2014 ACR/ARHP Annual Meeting
Predicting Successful Long-Term Treatment with Tumour Necrosis Factor-Alpha Inhibitors in Patients with Psoriatic Arthritis
Background/Purpose Short-term efficacy of tumour necrosis factor-alpha inhibitor (TNFi) therapy in patients with psoriatic arthritis (PsA) is well documented. In observational studies, effectiveness has mainly…
ACR Meeting Abstracts